Predictors for trismus in patients receiving radiotherapy by van der Geer, S. Joyce et al.
  
 University of Groningen
Predictors for trismus in patients receiving radiotherapy
van der Geer, S. Joyce; Kamstra, Jolanda I.; Roodenburg, Jan L. N.; van Leeuwen, Marianne;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van der Geer, S. J., Kamstra, J. I., Roodenburg, J. L. N., van Leeuwen, M., Reintsema, H., Langendijk, J.
A., & Dijkstra, P. U. (2016). Predictors for trismus in patients receiving radiotherapy. ACTA ONCOLOGICA,
55(11), 1318-1323. https://doi.org/10.1080/0284186X.2016.1223341
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
ORIGINAL ARTICLE
Predictors for trismus in patients receiving radiotherapy
S. Joyce van der Geera, Jolanda I. Kamstraa, Jan L.N. Roodenburga, Marianne van Leeuwena, Harry Reintsemaa,
Johannes A. Langendijkb and Pieter U. Dijkstraa,c
aDepartment of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
bDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
cDepartment of Rehabilitation, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
ABSTRACT
Background: Trismus, a restricted mouth opening in head and neck cancer patients may be caused by
tumor infiltration in masticatory muscles, radiation-induced fibrosis or scarring after surgery. It may
impede oral functioning severely. The aims of our study were to determine: (1) the incidence of trismus
at various time points; and (2) the patient, tumor, and treatment characteristics that predict the devel-
opment of trismus after radiotherapy in head and neck cancer patients using a large database
(n¼ 641).
Methods: Maximal mouth opening was measured prior to and 6, 12, 18, 24, 36, and 48 months after
radiotherapy. Patient, tumor, and treatment characteristics were analyzed as potential predictors for
trismus using a multivariable logistic regression analysis.
Results: At six months after radiotherapy, 28.1% of the patients without trismus prior to radiotherapy
developed trismus for the first time. At subsequent time points the incidence declined. Over a total
period of 48 months after radiotherapy, the incidence of trismus was 3.6 per 10 person years at risk.
Patients who had tumors located in the oral cavity, oropharynx or nasopharynx, and the salivary glands
or ear, and who had a longer overall treatment time of radiotherapy, were more likely to develop tris-
mus in the first six months after radiotherapy. Maximal mouth opening was a predictor for developing
trismus at all time points.
Conclusion: Incidence of trismus is 3.6 per 10 person years at risk. Tumor localization and overall treat-
ment time of radiotherapy are predictors for developing trismus the first six months after radiotherapy.
Maximal mouth opening is a significant predictor for developing trismus at all time points. Regular
measurements of maximal mouth opening are needed to predict trismus.
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Many patients with head and neck cancer suffer from trismus
(a mouth opening of 35 millimeters (mm) or less), especially
after radiotherapy [1,2]. Fibrosis is considered one of the bio-
logical mechanisms leading to late radiation-induced side
effects [3–5]. When the temporomandibular joint and masti-
catory muscles are irradiated, there is a risk of developing
trismus [6,7]. This risk increases in proportion to radiation
dose and irradiated volume of relevant anatomical structures
[2,8,9]. The reported prevalence of trismus after radiotherapy
for head and neck cancer ranges from 25% to 42% [2,9]. This
wide range in percentages can be explained by differences
in inclusion criteria, tumor characteristics, interval from treat-
ment and/or treatment modality in studies.
A previous study showed that the maximum mouth open-
ing decreases rapidly in the first nine months after radiother-
apy (mean decrease 2.4% per month). This restriction in
mouth opening may become severe and irreversible over
time [5]. Recently, a multivariate prediction model for the
course of mouth opening during and after radiotherapy was
published [10]. Although that model can be used to statistic-
ally predict the course of mouth opening, the clinical applica-
tion is limited because of its complexity. Prediction of trismus
may enable clinicians to subscribe preventive exercise ther-
apy (e.g. using the Dynasplint Trismus SystemVR (DTS) or the
TheraBiteVR Jaw Motion Rehabilitation SystemTM) for the
patients at risk [11,12]. In this prospective longitudinal cohort
study, we aimed to determine 1) the incidence of trismus at
various time points and 2) the patient, tumor, and treatment
characteristics that predict the development of trismus after




Head and neck cancer patients who received definitive or
postoperative external beam radiotherapy at the Department
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of Radiation Oncology of the University Medical Center
Groningen were entered in a prospective data registration
program. Prospective assessment of acute and late toxicity
and patient-reported outcome measures were included.
Radiotherapy was given alone or in combination with chemo-
therapy or cetuximab. For our study, we used data of
patients entered in the program from March 2007 until June
2011. The Ethics Committee approved our study and the
study was carried out according to the regulations of our
institute. Patients were invited to participate in this program
and asked for permission to use their data for the program
and other scientific purposes. Refusal of participation was
recorded in their medical record.
Patients receiving radiotherapy for a primary tumor located
outside the head and neck region, intra-cranially, in the nasal
vestibule, or on the skin, were excluded from the analyses
because treatment of these tumors were not expected to
influence mouth opening. Patients without data about max-
imal mouth opening were excluded, as well as patients who
died during radiotherapy or within six months thereafter.
Data
Patient characteristics were sex (male, female), age at start of
radiotherapy (years), deceased (yes, no), dental status (den-
tate, edentulous, partially edentulous, unknown), and change
in dental status (yes, no). Tumor characteristics were localiza-
tion of the primary tumor (oral cavity, oropharynx or naso-
pharynx, salivary glands or ear, hypopharynx or supraglottic
larynx, glottic or subglottical larynx, nasal cavity or maxillary
sinus, unknown primary tumor), squamous cell carcinoma
(yes, no), and T classification based on the Union for
International Cancer Control (UICC) TNM classification 2009
(T0, T1, T2, T3, T4, unknown). Treatment characteristics
recorded were radiotherapy primary tumor (yes, no), total
dose of radiation (Gy), fraction dose of radiation (Gy), overall
treatment time of radiotherapy (months), surgery (yes, no),
neck dissection (yes, no), chemotherapy (yes, no), and exer-
cise therapy for trismus (yes, no).
Mouth opening
Prior to radiotherapy (T0), maximal mouth opening was
measured in mm, using a sliding caliper. Maximal mouth
opening measurements were performed by well instructed
nurses. All concerned nurses were trained in measuring max-
imal mouth opening by the head and neck radiation oncolo-
gists prior to the measurements. A limited number of nurses
were working at the Department of Radiation Oncology dur-
ing the study period.
Patients were asked to open their mouth as far as pos-
sible and the distance between the incisal edges of the
11 and 41 (or of the dental prosthesis) was measured.
When patients were edentulous and did not wear a dental
prosthesis, the alveolar ridge of mandible and/or maxilla
was used (region 11 and 41). The maximal mouth opening
was measured again during subsequent time points: 6 (T6),
12 (T12), 18 (T18), 24 (T24), 36 (T36), and 48 (T48) months
after radiotherapy. Changes in dental status were recorded
in the database.
Trismus was noted as present if maximal mouth opening
was 35mm or less. This cutoff point correlates best with per-
ceived restrictions of mouth opening [13,14].
Statistics
Analyses were performed using IBM SPSS Statistics Program
version 22.0. Patients with no missing mouth opening meas-
urements before their last recorded measurement were
coded as ‘without missing data’ and patients with missing
mouth opening measurements were coded as ‘missing data’.
Differences between patients with and without missing data
were analyzed using a v2-test, t-test for independent sam-
ples, or Mann-Whitney U-test, as appropriate. To calculate
the incidence of trismus, the number of patients who devel-
oped trismus for the first time after radiotherapy was calcu-
lated and divided by the number of patients who were at
risk of developing trismus for the first time. Patients having
trismus prior to radiotherapy were excluded from the inci-
dence analyses. Patients who had no trismus at the last
assessment, but with missing data at previous time points,
were also excluded from the incidence analyses as they
might have had trismus at those missing time points. To cal-
culate the incidence based on person years at risk, patients
with missing data before the time point when trismus was
recorded for the first time and who had no trismus prior to
radiotherapy, were included in the calculation; we assumed
that trismus developed half way in the period between two
recorded time points.
Multivariate logistic regression analyses were performed
to predict trismus at the subsequent time points. Patient,
tumor, and treatment characteristics were selected as poten-
tial predictors. For example, at T0, we used potential pre-
dictor variables to predict the risk of developing trismus at
T6. Similarly, at T6 we used potential predictor variables to
predict the risk of developing trismus at T12.
The potential risk factors: sex, age, localization of the pri-
mary tumor, squamous cell carcinoma, T4 classification, total
dose of radiation, fraction dose of radiation, overall treatment
time of radiotherapy, surgery, chemotherapy, and maximal
mouth opening at previous time point were entered in the
model [9,10,14–16]. Thereafter, variables were removed if
they did not contribute significantly to the regression equa-
tion (p< .05). As part of validation, the results of the calcula-
tions of incidence and of the regression analyses were
compared to the results of patients without missing data.
From the results of the regression analyses, the risk of devel-
oping trismus was calculated for a hypothetical patient who
had a nasopharynx carcinoma and was treated with radio-
therapy for six weeks.
Results
Patient, tumor, and treatment characteristics
Data from 788 patients who received radiotherapy in the head
and neck region were entered in the prospective data
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registration program; in total, 145 patients were excluded
according to the exclusion criteria [10]. Additionally, two
patients with a rare type of tumor (myxofibrosarcoma and epi-
theloid angiosarcoma) were excluded for statistical reasons.
Thus, the study population consisted of 641 patients (81.3%),
involving 436 patients without missing data regarding max-
imal mouth opening. Patients with and patients without miss-
ing data were compared. Significant differences between
these groups were found in the variables deceased, overall
treatment time of radiotherapy, and chemotherapy (Table 1).
Of the 641 patients, 42 (6.6%) changed dental status; 20
of these patients (3.1%) changed from dentate to edentulous,
15 patients (1.9%) changed from partially edentulous to
edentulous, and five patients (0.8%) changed from dentate
to partially edentulous. The change in dental status was
unknown for two patients (0.3%).
Prevalence
Prior to radiotherapy, 34.8% of the patients had trismus
(Table 2). Relative to patients who did not have trismus prior
to radiotherapy, trismus prior to radiotherapy was signifi-
cantly associated with female sex (p< .001), a higher age
(p¼ .002), tumors located in the oral cavity and salivary
glands or ear (p< .001), T4 tumors (p¼ .002), and a history of
surgery (p< .001) (Supplementary Table A1, available online).
Incidence
The incidence of trismus in the total period of 48 months
after radiotherapy was 3.6 per 10 person years at risk. At T6,
28.1% of the patients at risk developed trismus for the first
time (Table 2). Patients with a tumor located in the orophar-
ynx or nasopharynx (p¼ .004), and with a history of chemo-
therapy (p¼ .024) were more likely to develop trismus at T6
(Supplementary Table A1, available online). The incidence of
trismus declined at subsequent time points. No new cases of
trismus developed after T36 (Table 2).
No major differences were seen when the results of the
incidence of trismus of the study population were compared
to the results of the patients without missing data
(Supplementary Table A2, available online).
Multivariate logistic regression analyses
In the prediction model, a smaller mouth opening at T0, a
longer overall treatment time of radiotherapy, and tumors
located in the oral cavity, oropharynx or nasopharynx, and
Table 1. Patient, tumor, and treatment characteristics.
Study population Without missing data With missing data
n (%) n (%) n (%) p
Patient characteristics
Male sex 451 (70.4) 312 (71.6) 139 (67.8) .332
Age (years); Mean (SD) 62.3 (12.5) 62.4 (12.6) 61.9 (12.5) .698†
Deceased 199 (31.0) 161 (36.9) 38 (18.5) <.001
Dental status .510
Dentulous 241 (37.6) 156 (35.8) 85 (41.5)
Edentulous 319 (49.8) 219 (50.2) 100 (48.8)
Partially edentulous 77 (12.0) 53 (12.2) 18 (8.8)
Unknown 4 (0.6) 3 (0.7) 1 (0.5)
Change in dental status 42 (6.6) 30 (6.9) 12 (5.9)
Tumor characteristics
Localization of the primary tumor .584
Oral cavity 132 (20.6) 93 (21.3) 39 (19.0)
Oropharynx or nasopharynx 162 (25.3) 109 (25.0) 53 (25.9)
Salivary glands or ear 66 (10.3) 46 (10.6) 20 (9.8)
Hypopharynx or supraglottic larynx 115 (17.9) 76 (17.4) 39 (19.0)
Glottic or subglottic larynx 116 (18.1) 77 (17.7) 39 (19.0)
Nasal cavity or maxillary sinus 24 (3.7) 20 (4.6) 4 (2.0)
Unknown primary 26 (4.1) 15 (3.4) 11 (5.4)
Squamous cell carcinoma 512 (79.9) 351 (80.5) 161 (78.5) .562
T classification .931
T0 6 (0.9) 3 (0.7) 3 (1.5)
T1 112 (17.5) 77 (17.7) 35 (17.1)
T2 191 (29.8) 129 (29.6) 62 (30.2)
T3 99 (15.4) 68 (15.6) 31 (15.1)
T4 183 (28.5) 128 (29.4) 55 (26.8)
Unknown 38 (5.9) 25 (5.7) 13 (6.3)
Treatment characteristics
Radiotherapy primary tumor 610 (95.2) 418 (95.7) 192 (96.6) .410
Total dose of irradiation; Med (IQR) 70 (66–70) 66 (66–70) 70 (66–70) .413‡
Fraction dose of irradiation; Med (IQR) 2 (2–2) 2 (2–2) 2 (2–2) .709‡
Overall treatment time of radiotherapy (months); Med (IQR) 1.28 (1.3–1.5) 1.4 (1.3–1.5) 1.3 (1.2–1.4) .041‡
Surgery 248 (38.7) 175 (40.1) 73 (35.6) .272
Neck dissection 316 (33.7) 142 (32.6) 74 (36.1) .378
Chemotherapy 465 (72.5) 137 (31.4) 39 (19.0) .001
Exercise therapy for trismus 21 (3.3) 14 (3.2) 7 (3.4) .893
IQR: interquartile range; Med: median.p of the comparison between patients with and patients without missing data; †Results of t-test for independent samples; ‡Results of Mann-Whitney U-test. All
other p-values were the result of v2-test.
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the salivary glands or ear all resulted in significantly higher
odds for developing trismus at T6. A smaller mouth opening at
T6 and a tumor located in the oral cavity led to significantly
higher odds of developing trismus at T12. However, for the pre-
diction of developing trismus at T18, T24, T36, and T48, only
mouth opening at the previous time point contributed signifi-
cantly to the regression equation (Table 3).
No major differences were seen when the results of the
regression analyses of the study population were compared
to the results of the patients without missing data
(Supplementary Table A3, available online).
Risk calculation
As an example of applying the prediction model, arbitrarily
chosen characteristics of the hypothetical patient
Table 3. Output multivariate logistic regression analyses at T6, T12, T18, T24, T36, and T48.
Prediction mouth opening at T6 % b OR 95% CI OR LL 95% CI OR UL p (b)
% correctly predicted (Nagelkerke’s R2) 73.9 (0.334)
Mouth opening at T0 .09 0.91 0.89 0.93 <.001
Overall treatment time (in months) 1.72 5.58 1.80 17.32 .003
Oral cavity .82 2.28 1.06 4.91 .035
Oropharynx or nasopharynx 1.44 4.21 2.04 8.68 <.001
Salivary glands or ear 1.15 3.15 1.29 7.68 .012
Hypopharynx or supraglottic larynx .31 1.37 0.61 3.06 .445
Nasal cavity or maxillary sinus .69 2.00 0.54 7.41 .299
Unknown primary tumor .62 0.54 0.13 2.29 .401
Constant .19 1.20 .840
Prediction mouth opening at T12
% correctly predicted (Nagelkerke’s R2) 81.4 (0.506)
Mouth opening at T6 .20 0.82 0.79 0.86 <.001
Oral cavity 1.32 3.74 1.44 9.74 .007
Oropharynx or nasopharynx 0.61 1.83 0.76 4.42 .177
Salivary glands or ear 0.74 2.10 0.78 5.65 .140
Hypopharynx or supraglottic larynx 0.53 1.70 0.61 4.69 .309
Nasal cavity or maxillary sinus 1.13 3.09 0.72 13.33 .130
Unknown primary tumor 1.05 2.86 0.73 11.24 .133
Constant 5.89 361.58 <.001
Prediction mouth opening at T18
% correctly predicted (Nagelkerke’s R2) 81.7 (0.533)
Mouth opening at T12 0.22 0.81 0.77 0.84 <.001
Constant 7.53 1858.14 <.001
Prediction mouth opening at T24
% correctly predicted (Nagelkerke’s R2) 85.4 (0.657)
Mouth opening at T18 0.27 0.76 0.72 0.81 <.001
Constant 9.26 10535.35 <.001
Prediction mouth opening at T36
% correctly predicted (Nagelkerke’s R2) 88.3 (0.655)
Mouth opening at T24 0.28 0.76 0.70 0.81 <.001
Constant 9.70 16309.72 <.001
Predict mouth opening at T48
% correctly predicted (Nagelkerke’s R2) 85.0 (0.641)
Mouth opening at T36 0.27 0.76 0.69 0.84 <.001
Constant 9.23 10195.45 <.001
b: regression coefficient; Nagelkerke R2: Nagelkerke’s R square; OR: odds ratio; 95% CI OR LL: 95% confidence interval of OR lower limit; 95% CI OR UL: 95% con-
fidence interval of OR upper limit.Percentage correctly predicted.
Glottic or subglottic larynx is used as reference category.
Table 2. Trismus at T0, T6, T12, T18, T24, T36, and T48.
Total No trismus Trismus No trismus to Trismus Trismus to no trismus At risk for trismus for the first time Incidence
Time point N n (%) n (%) n (%) n (%) n n (%)
T0 414 270 (65.2) 144 (34.8) 76 (28.1) 45 (31.3) 270 76 (28.1)
T6 239 (57.7) 175 (42.3)
T6 365 225 (61.6) 140 (38.4) 35 (15.6) 39 (27.9) 164 19 (11.6)
T12 229 (62.7) 136 (37.3)
T12 349 225 (64.5) 124 (35.5) 40 (17.8) 27 (21.8) 126 14 (11.1)
T18 212 (60.7) 137 (39.3)
T18 328 192 (58.5) 136 (41.5) 19 (9.9) 29 (21.3) 95 7 (7.4)
T24 202 (61.6) 126 (38.4)
T24 213 133 (62.4) 80 (37.6) 13 (9.8) 13 (16.3) 51 3 (5.9)
T36 133 (62.4) 80 (37.6)
T36 114 74 (64.9) 40 (35.1) 8 (10.8) 3 (7.5) 22 0
T48 69 (60.5) 45 (39.5)
Number of patients for which observations are available for the time period.
For example: Initially, 270 patients had no trismus, of which 76 changed status, they developed trismus and 194 did not change status, they remained without
trismus. In total 144 patients did have trismus of which 45 changed status to ‘no trismus’ and 99 did not change status, they kept trismus. At T0, 270 patients
were at risk to develop trismus for the first time. Of these 270 patients, 76 developed trismus for the first time.
ACTA ONCOLOGICA 1321
(nasopharynx carcinoma, radiotherapy for six weeks) were
entered in the multivariable logistic regression equation
(Figure 1).
No major differences were seen when the results of the
risk calculation of the study population were compared to
the results of the patients without missing data
(Supplementary Figure A1, available online).
Discussion
Key results
In our population of head and neck cancer patients the inci-
dence of trismus is highest six months after radiotherapy and
declines thereafter (Table 2). The incidence of trismus was 3.6
per 10 person years at risk, calculated over the total period
of 48 months after radiotherapy. The best predictors for
developing trismus in the first six months after radiotherapy
are tumors located in the oral cavity, oropharynx or naso-
pharynx and the salivary glands or ear, and a longer overall
treatment time of radiotherapy. At all time points, maximal
mouth opening measurement at the previous time point was
a significant predictor for developing trismus at the subse-
quent time point (Table 3).
Prevalence
As stated earlier, already 34.8% of the head and neck cancer
patients had a trismus prior to radiotherapy. Patients with a
tumor located in the oral cavity and salivary glands or ear were
more likely to have trismus prior to radiotherapy, possibly
because of tumor infiltration near the masticatory muscles.
Additionally, patients with a history of surgery were more likely
to have trismus prior to have radiotherapy, probably due to
the formation of scarring after surgery.
Incidence
For the calculation of incidence, most patients had measure-
ments at time points T0 and T6. Thereafter, the number of
patients who had subsequent measurements declined. This
decline was due to patients who deceased after T6 and due
to patients for whom measurements were not completed in
the inclusion period (right censored data).
The results in Table 2 show that the incidence of tris-
mus was highest from T0 to T6. Thereafter, the incidence
for trismus declined. This was also observed in two other
studies [5,17]. The first study showed a rapid decrease in
mouth opening between the first and ninth month after
radiotherapy [5]. The second study showed a rapid
decrease in maximal mouth opening of 0.9% per month
during the first six months after radiotherapy and this
reduction decreased over time to 0.3% per month, and
reduced even further between the second and fifth year
after radiotherapy [17]. Both studies included only patients
suffering from nasopharyngeal carcinomas. In our study,
patients with head and neck tumors at different localiza-
tions were included, which probably increases the general-
izability of our results.
The decline in incidence at subsequent time points can
be related to recovery from the short-term effects of radio-
therapy. In a small group of patients with nasopharyngeal
carcinomas (n¼ 17), recovery occurred between the 5th
and 12th month after radiotherapy [18]. Due to this recov-
ery, patients with trismus at a time point can change to
no trismus at a later time point. Remarkably, in our study,
recovery from trismus still occurred up to 48 months after
radiotherapy (Table 2).
Risk calculation
A longer overall treatment time of radiotherapy leads to a
higher risk of developing trismus six months after radio-
therapy. A longer overall treatment time could be a risk
factor due to patients receiving chemotherapy or not. In
general, in our center, patients who receive chemotherapy
are treated for seven weeks, whereas patients who receive
radiotherapy only are treated for six weeks. It could be
assumed that patients with a longer overall treatment time
of radiotherapy includes predominantly patients who
received chemotherapy. A combination of chemotherapy
and radiotherapy is a more intensive and extensive
approach, which would be expected to lead to more fibro-
sis and hence more trismus.
In our study, we found no significant association
between the prescribed total dose and fraction dose of
radiotherapy and trismus. In a retrospective study, an
association between difficulty in opening the mouth and
the radiation dose to the masseter muscles, pterygoid
muscles, coronoid process, and mandibular condyle was
found [19]. It is expected that significant dose-effect rela-
tionships will be found when using specific three-dimen-
sional (3D) distribution parameters to relevant anatomical
structures.
Future studies
Analysis of specific dose distribution and anatomical struc-
tures such as the masticator muscles and temporomandibular
Figure 1. Risk of developing trismus at T6, T12, T18, T24, T36, and T48.
Arbitrarily chosen characteristics of a hypothetical patient were entered in the
multivariable logistic regression equation as a reference category. This hypo-
thetical patient had a nasopharynx carcinoma and was treated with radiother-
apy for 6 weeks.
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joint could improve the identification of patients at risk of
developing trismus. We did not include the effect of the 3D
dose distributions in our analysis as this is part of a future,
separate project in which multivariable normal-tissue compli-
cation probability models will be used.
Study limitations
A limitation of our study was the measurement procedure of
mouth opening that was performed by different assessors of
the Department of Radiation Oncology, which might have
introduced a measurement error. However, it is stated that
maximal mouth opening can be assessed reliably, regardless
of the assessor, therefore we expect this error to be
small [20].
Another limitation was the change in dental status during
the course of the study. A relatively small percentage of the
patient changed dental status (6.6%). Most patients changed
for dentate to (partially) edentulous or from partially edentu-
lous to edentulous, thereby resulting predominantly in an
increase of mouth opening measurement. However, this does
not reflect real recovery from trismus itself. The calendar
dates regarding dental status changes were not available in
the database, thus no direct link between dental status and
the variation in number of patients with and without trismus
could be made.
No other causes for trismus than secondary to the head
and neck cancer were investigated.
Conclusion
The incidence of trismus is 3.6 per 10 person years at risk
based on a follow-up of 48 months after radiotherapy. Tumor
localization and overall treatment time of radiotherapy are
significant risk factors for developing trismus at T6. Maximal
mouth opening at any time point is a significant predictor
for developing trismus at all subsequent time points. As max-
imal mouth opening is an important predictor, regular meas-
urements of maximal mouth opening are needed to predict
trismus. High-risk patients identified by the presence of pre-
dictors for trismus can be offered preventive measures.
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